A5046303408- CAR-T cell therapy research
- PARP inhibition in cancer therapy
- Immune Cell Function and Interaction
- CRISPR and Genetic Engineering
- Photodynamic Therapy Research Studies
- Nanoparticles: synthesis and applications
- Nanoplatforms for cancer theranostics
- Plant Virus Research Studies
- Virus-based gene therapy research
- Acute Lymphoblastic Leukemia research
- Viral Infectious Diseases and Gene Expression in Insects
- Radio Frequency Integrated Circuit Design
- Gold and Silver Nanoparticles Synthesis and Applications
- Cancer Immunotherapy and Biomarkers
- Manufacturing Process and Optimization
- Nanoparticle-Based Drug Delivery
- Nanowire Synthesis and Applications
- Chronic Myeloid Leukemia Treatments
- Glioma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- RNA Interference and Gene Delivery
- Cancer Genomics and Diagnostics
Universidade de São Paulo
2020-2024
University of Wisconsin–Madison
2022
Universidade de Ribeirão Preto
2020
Chimeric antigen receptor (CAR) engineering of natural killer (NK) cells have shown promising results in early-phase clinical studies. However, advancing CAR-NK cell therapeutic efficacy is imperative. In this study, we investigated the impact a fourth generation CD19-targeted CAR (CAR.19) co-expressing IL-27 on NK-92 cells. We observed significant improvement proliferation and cytotoxicity activity against B-cell cancer lines, both vitro xenograft mouse lymphoma model. Our systematic...
Abstract A number of different metallic nanoparticles have been extensively investigated in recent years based on their diverse potential biomedical and cancer applications, antibacterial activity, chemical properties. Here, silver nitroprusside (AgNPs) were prepared from nitrate sodium nitroprusside, anticancer activity was evaluated. AgNPs characterized by Fourier transform infrared (FTIR), X-ray diffraction (DRX), scanning electron microscopy (SEM), dispersive energy spectroscopy (EDX),...
Detection of t(9;22), and consequent BCR::ABL1 fusion, is still a marker worse prognosis for acute lymphoblastic leukemia (ALL), with resistance to tyrosine-kinase inhibitor therapy being major obstacle in the clinical practice this subset patients. In study, we investigated effectiveness targeting poly-ADP-ribose polymerase (PARP) model p190+ ALL, most common isoform afflict ALL patients, demonstrated use experimental PARP (PARPi), AZD2461, as therapeutic option cytotoxic capabilities...
Abstract Detection of t(9;22), and consequent BCR-ABL1 fusion, is still a marker worse prognosis for acute lymphoblastic leukemia (ALL), with resistance to tyrosine-kinase inhibitor therapy being major obstacle in the clinical practice this subset patients. In study, we investigated effectiveness targeting poly-ADP-ribose polymerase (PARP) model BCR-ABL p190 + ALL, most common isoform afflict ALL patients, demonstrated use experimental PARP (PARPi), AZD2461, as therapeutic option cytotoxic...
<h3>Background</h3> Chimeric antigen receptor (CAR) T-cells are engineered immune cells that can be taken from a patient and redirected to fight cancer. Recently, we developed virus-free process create anti-GD2 CAR T using CRISPR-Cas9 ribonucleoproteins endows with stem cell memory-like less exhausted phenotype improves their ability induce regression of GD2 positive solid tumors. <h3>Methods</h3> To improve this workflow, systematically modified the media conditions, electroporation timing,...